Deutsche Bank Aktiengesellschaft Increases Sutro Biopharma (NASDAQ:STRO) Price Target to $55.00

Sutro Biopharma (NASDAQ:STRO) had its price objective increased by analysts at Deutsche Bank Aktiengesellschaft from $51.00 to $55.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential upside of 120.79% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Monday, December 22nd. HC Wainwright raised shares of Sutro Biopharma from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $10.00 to $28.00 in a research report on Tuesday. Citizens Jmp upgraded shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 target price for the company in a research note on Tuesday, January 20th. Wedbush reissued a “neutral” rating and issued a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a report on Tuesday, December 2nd. Finally, Wells Fargo & Company upgraded shares of Sutro Biopharma from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $8.00 to $27.00 in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.29.

Sutro Biopharma Stock Up 6.0%

STRO opened at $24.91 on Wednesday. The firm has a market capitalization of $212.08 million, a P/E ratio of -0.95 and a beta of 1.47. The stock’s 50 day moving average price is $18.84 and its two-hundred day moving average price is $12.84. Sutro Biopharma has a 12-month low of $5.23 and a 12-month high of $26.54.

Institutional Trading of Sutro Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. Velan Capital Investment Management LP raised its stake in shares of Sutro Biopharma by 197.1% in the second quarter. Velan Capital Investment Management LP now owns 3,060,000 shares of the company’s stock valued at $2,185,000 after purchasing an additional 2,030,000 shares in the last quarter. AQR Capital Management LLC boosted its stake in Sutro Biopharma by 1,052.8% during the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after buying an additional 1,206,330 shares in the last quarter. Jane Street Group LLC acquired a new stake in Sutro Biopharma during the second quarter worth $492,000. Jacobs Levy Equity Management Inc. bought a new stake in Sutro Biopharma in the 3rd quarter valued at $387,000. Finally, Two Sigma Investments LP increased its holdings in Sutro Biopharma by 244.8% in the 3rd quarter. Two Sigma Investments LP now owns 396,785 shares of the company’s stock valued at $345,000 after buying an additional 281,717 shares during the period. 96.99% of the stock is currently owned by institutional investors.

Key Sutro Biopharma News

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target to $55 from $51 and maintained a “Buy” rating — a sizable upside vs. the current price, which supports bullish sentiment. Benzinga
• Positive Sentiment: Truist Financial upgraded Sutro to “Strong-Buy,” reinforcing buy-side momentum among institutional analysts. Zacks
• Positive Sentiment: Wells Fargo upgraded STRO to “Overweight,” adding another supportive brokerage view that can attract investors. Wells Fargo Upgrade
• Positive Sentiment: HC Wainwright also issued an upgrade/coverage item (Buy, $28 PT) in recent press coverage, adding to the cluster of buy-side recommendations. AmericanBankingNews – HC Wainwright Upgrade
• Neutral Sentiment: HC Wainwright published a FY2030 estimate (EPS forecast of ($4.43)), which is informational for longer-term modeling but not a catalyst on its own. MarketBeat
• Negative Sentiment: Offsetting the upgrades, HC Wainwright sharply lowered near- and multi-year EPS forecasts across Q1–Q4 2026 and FY2026–FY2029 (e.g., FY2026 cut to ($10.32) from ($4.25); FY2027–FY2029 also pushed materially lower), while retaining a Buy rating and $28 PT — these large downside revisions imply greater near-term dilution, higher cash burn or program changes and represent a negative earnings/cash-flow signal investors should model into valuations. MarketBeat – Estimates

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.